Company / Capital Expenditures
Emergent BioSolutions Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$13.8M
FY2025
5-year range
$13.8M / $224.1M
FY2021-FY2025
Trend
-39.7%
vs FY2024
Sector context
#51 of 194
Health Care
What the data says
At $14M, Emergent BioSolutions Inc.'s capital expenditures ranks #51 of 194 in the Health Care sector. Capital Expenditures has declined for 4 consecutive years, from $224M in FY2021 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of -37.2%.
Declined from $52M to $14M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -50.8%
- 5-Year CAGR
- -37.2%
- 10-Year CAGR
- -
Sector benchmark
#51 of 194 in Health CareTop 26% of 194This company $13.8M Sector average $117.5M
▼
-88.3% below sector average
Key checks
Key Insights
- Emergent BioSolutions Inc.'s capital expenditures has declined for 4 consecutive years.
- 5-year CAGR of -37.2%, indicating a declining trend.
- In FY2025, capital expenditures decreased 39.7% year-over-year.
- Ranks #51 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.8M | -39.7% |
| FY2024 | $22.9M | -55.6% |
| FY2023 | $51.6M | -55.4% |
| FY2022 | $115.8M | -48.3% |
| FY2021 | $224.1M | +58.9% |
| FY2020 | $141.0M | +62.3% |
| FY2019 | $86.9M | +14.0% |
| FY2018 | $76.2M | +39.1% |
| FY2017 | $54.8M | -28.1% |
| FY2016 | $76.2M | +70.0% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026